<?xml version="1.0" encoding="UTF-8"?>
<Label drug="panhematin" track="TAC2017_ADR">
  <Text>
    <Section name="adverse reactions" id="S1">    ADVERSE REACTIONS

  Clinical Trials Experience

  Phlebitis with or without leucocytosis and with or without mild pyrexia has occurred after administration of hematin through small arm veins.



   Post-marketing Experience

  Reversible renal shutdown has occurred with administration of excessive doses (See "  PRECAUTIONS  " section).



 There have been post-marketing literature reports of thrombocytopenia and coagulopathy (including prolonged prothrombin time and prolonged partial thromboplastin time) in patients receiving PANHEMATIN.[  8  ] Iron overload and serum ferritin increased have also been reported (See "  PRECAUTIONS  " section).



   To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases at 1-888-575-8344 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  
</Section>
    <Section name="boxed warnings" id="S2">

    BOXED WARNING: 

  PANHEMATIN (hemin for injection) should only be used by physicians experienced in the management of porphyrias in hospitals where the recommended clinical and laboratory diagnostic and monitoring techniques are available.



 PANHEMATIN therapy should be considered after an appropriate period of alternate therapy (i.e., 400 g glucose/day for 1 to 2 days). (See "  WARNINGS  ", "  PRECAUTIONS  " and "  DOSAGE AND ADMINISTRATION  " sections.)
</Section>
  </Text>
  <Mentions />
  <Relations />
  <Reactions />
</Label>
